Imatinib Eg

Imatinib, the active ingredient in Imatinib Eg, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It treats chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imatinib Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib is a targeted tyrosine‑kinase inhibitor used in several hematologic and solid‑tumor indications. - Chronic myeloid leukemia: suppresses BCR‑ABL driven proliferation and induces remission. - Philadelphia chromosome‑positive acute lymphoblastic leukemia: blocks leukemic cell growth and improves survival. - Gastrointestinal stromal tumor: inhibits c‑KIT and PDGFR signaling to reduce tumor size and progression.

Imatinib may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, especially of the ankles. - Muscle cramps: intermittent painful contractions. - Fatigue: generalized tiredness. - Diarrhea: loose stools, sometimes watery. - Rash: mild skin eruptions.

Serious or Rare Side Effects: - Neutropenia: significant drop in white blood cells. - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiac failure: reduced heart function, especially in patients with pre‑existing disease. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Pulmonary hypertension: increased pressure in lung arteries. - Hemorrhage: abnormal bleeding tendencies.

Before initiating therapy, clinicians should assess baseline organ function and monitor patients regularly. - Blood count monitoring: perform complete blood counts weekly for the first month, then periodically. - Liver function assessment: check transaminases and bilirubin before treatment and during therapy. - Cardiac evaluation: obtain baseline ECG in patients with cardiac history. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks; data are limited. - Storage: Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Imatinib interacts with several drugs that affect its metabolism or pharmacodynamic profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase imatinib exposure and toxicity. - Potent CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy by lowering plasma levels. - Concomitant use with QT‑prolonging agents (e.g., sotalol): can increase risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Warfarin: imatinib may enhance anticoagulant effect; monitor INR closely. - Proton pump inhibitors: may modestly affect absorption; observe clinical response. - Vaccines (live attenuated): consider timing, as immunosuppression could reduce efficacy.